

# Principles of Pharmacology Curriculum Improvement Benchmarks

Mark Dershwitz & Jill Zitzewitz

AY 20-21

Category	Sample benchmarks (pick or edit from the following)
<p>Increase engaged learning (small group, flipped classroom, problem-based learning, simulation, etc)</p> <p>Decrease traditional lectures (large group, limited interaction, static content)</p>	<p>The lecture entitled, "Pharmacodynamics III," by Dr. Zitzewitz, is being converted into an interactive session that is planned to involve breakout groups. It is a work in progress.</p>
Identify and remove unintended redundancy	<p>We have identified no unintended redundancies in our course; however, we will continue to reach out to faculty in other courses to draw connections between related material.</p>
<p>Incorporate <u>at least 1 new aspect of EACH of these 3 priority content areas</u> into the course (or block for larger courses) using the Instructional Method of your choice</p>	<ol style="list-style-type: none"> <li>1. Racism: The self-study session on drug development, originally developed by Dr. McCullough, is being modified by Dr. Zitzewitz to include information on the need for, and the historic lack of, inclusion of people of color in clinical trials.</li> <li>2. SDH: While it is a work in progress, a discussion of how social determinants of health impact the retention of people from diverse backgrounds in clinical trials will be incorporated into the clinical trial self-study module.</li> <li>3. Health Systems Sciences: We have been not yet been able to identify a clear session that is relevant to HSS, but it may be possible to incorporate some of the basic principles of HSS into the introductory POP session, or the self study clinical trials module and the self study IRB approval session. We will continue to think about this topic and how to best address it our course. Additionally, Dr. Zitzewitz, upon the suggestion of Max Rosen, has also been working with Rick Jacobs to discus plans for an <u>optional</u> evening forum on clinical trials, which would include a the patient perspective on accessing a clinical trial and the industry perspective on clinical trial development. Again this is a work in progress, but may occur in October if it can be arranged in time. In future years for POP, the clinical trial session will likely be incorporated into a small group session to allow more discussion of each of these priority areas.</li> </ol>
All course leaders participate in DRIVE (Diversity, Representation and Inclusion for Value in Education) workshop	<p>Dr. Dershwitz completed the DRIVE workshop.</p> <p>Dr. Zitzewitz will review the DRIVE workshop on the OUME workshop before the course starts, and she will take the Stanford course on Unconscious Bias in Medicine.</p>